118 related articles for article (PubMed ID: 34358968)
41. Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic cell-dependent NFATc1 pathways.
Yamashita T; Uehara S; Udagawa N; Li F; Kadota S; Esumi H; Kobayashi Y; Takahashi N
PLoS One; 2014; 9(1):e85878. PubMed ID: 24465763
[TBL] [Abstract][Full Text] [Related]
42. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation.
Song I; Kim JH; Kim K; Jin HM; Youn BU; Kim N
FEBS Lett; 2009 Jul; 583(14):2435-40. PubMed ID: 19576893
[TBL] [Abstract][Full Text] [Related]
43. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.
Hasegawa H; Kido S; Tomomura M; Fujimoto K; Ohi M; Kiyomura M; Kanegae H; Inaba A; Sakagami H; Tomomura A
J Biol Chem; 2010 Aug; 285(33):25448-57. PubMed ID: 20547767
[TBL] [Abstract][Full Text] [Related]
44. MiR-143 Inhibits Osteoclastogenesis by Targeting RANK and NF-κB and MAPK Signaling Pathways.
He X; Zhu L; An L; Zhang J
Curr Mol Pharmacol; 2020; 13(3):224-232. PubMed ID: 31951177
[TBL] [Abstract][Full Text] [Related]
45. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells.
Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J
Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653
[TBL] [Abstract][Full Text] [Related]
46. Zinc inhibits osteoclast differentiation by suppression of Ca2+-Calcineurin-NFATc1 signaling pathway.
Park KH; Park B; Yoon DS; Kwon SH; Shin DM; Lee JW; Lee HG; Shim JH; Park JH; Lee JM
Cell Commun Signal; 2013 Oct; 11():74. PubMed ID: 24088289
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
48. Mitf regulates osteoclastogenesis by modulating NFATc1 activity.
Lu SY; Li M; Lin YL
Exp Cell Res; 2014 Oct; 328(1):32-43. PubMed ID: 25152440
[TBL] [Abstract][Full Text] [Related]
49. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T
J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684
[TBL] [Abstract][Full Text] [Related]
50. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
[TBL] [Abstract][Full Text] [Related]
51. Novel extraneural role of neurite outgrowth inhibitor A: modulation of osteoclastogenesis via positive feedback regulation of nuclear factor of activated T cell cytoplasmic 1.
Lee Y; Kim HJ; Park CK; Kim WS; Lee ZH; Kim HH
J Bone Miner Res; 2012 May; 27(5):1043-54. PubMed ID: 22392845
[TBL] [Abstract][Full Text] [Related]
52. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos.
Matsuo K; Galson DL; Zhao C; Peng L; Laplace C; Wang KZ; Bachler MA; Amano H; Aburatani H; Ishikawa H; Wagner EF
J Biol Chem; 2004 Jun; 279(25):26475-80. PubMed ID: 15073183
[TBL] [Abstract][Full Text] [Related]
53. cIAP1/2 negatively regulate RANKL-induced osteoclastogenesis through the inhibition of NFATc1 expression.
Yamaguchi N; Yokota M; Taguchi Y; Gohda J; Inoue J
Genes Cells; 2012 Dec; 17(12):971-81. PubMed ID: 23126497
[TBL] [Abstract][Full Text] [Related]
54. Identification and analysis of function of a novel splicing variant of mouse receptor activator of NF-κB.
Mukai S; Kitazawa R; Ishii J; Kondo T; Hakozaki A; Horiuchi K; Haraguch R; Mori K; Kitazawa S
Mol Cell Biochem; 2011 Apr; 350(1-2):29-38. PubMed ID: 21153864
[TBL] [Abstract][Full Text] [Related]
55. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
Xu H; Chen F; Liu T; Xu J; Li J; Jiang L; Wang X; Sheng J
Chem Biol Interact; 2020 Nov; 331():109235. PubMed ID: 32971123
[TBL] [Abstract][Full Text] [Related]
56. Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling.
Strålberg F; Henning P; Gjertsson I; Kindlund B; Souza PP; Persson E; Abrahamson M; Kasprzykowski F; Grubb A; Lerner UH
FASEB J; 2013 Jul; 27(7):2687-701. PubMed ID: 23572233
[TBL] [Abstract][Full Text] [Related]
57. High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-κB ligand in osteoblasts.
Lee HL; Bae OY; Baek KH; Kwon A; Hwang HR; Qadir AS; Park HJ; Woo KM; Ryoo HM; Baek JH
Bone; 2011 Aug; 49(2):242-9. PubMed ID: 21514407
[TBL] [Abstract][Full Text] [Related]
58. Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.
Lin X; Xiao Y; Chen Z; Ma J; Qiu W; Zhang K; Xu F; Dang K; Qian A
Mol Cell Endocrinol; 2019 Aug; 494():110494. PubMed ID: 31260729
[TBL] [Abstract][Full Text] [Related]
59. Diacylglycerol Kinase ζ (DGKζ) Is a Critical Regulator of Bone Homeostasis Via Modulation of c-Fos Levels in Osteoclasts.
Zamani A; Decker C; Cremasco V; Hughes L; Novack DV; Faccio R
J Bone Miner Res; 2015 Oct; 30(10):1852-63. PubMed ID: 25891971
[TBL] [Abstract][Full Text] [Related]
60. The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors.
Kwon OH; Lee CK; Lee YI; Paik SG; Lee HJ
Biochem Biophys Res Commun; 2005 Sep; 335(2):437-46. PubMed ID: 16083856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
